Propanc Biopharma (PPCB) Non Operating Income (2020 - 2025)
Propanc Biopharma (PPCB) posted quarterly Non Operating Income of $563340.0 for Q4 2025, up 359.84% year-over-year from $122507.3 in Q4 2024, and up 443.14% quarter-over-quarter from -$164174.0 in Q3 2025.
Propanc Biopharma (PPCB) Non Operating Income (2020 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Non Operating Income for 6 consecutive years, with $563340.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 359.84% year-over-year to $563340.0; the TTM figure through Dec 2025 stood at -$965682.0 (down 98.97% YoY), while the FY2025 annual figure was -$1.6 million, down 297.76% from the prior year.
- Non Operating Income climbed to $563340.0 in Q4 2025 per PPCB's latest filing, from -$164174.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $563340.0 in Q4 2025 and bottomed at -$938633.0 in Q1 2025.
- Historically, Non Operating Income has averaged -$177542.8 across 5 years, with a median of -$104085.5 in 2021.
- Annual changes were most pronounced in 2023 — Non Operating Income plunged 3982.26% — and 2025, when it surged 359.84%.
- Propanc Biopharma's Non Operating Income stood at -$451973.0 in 2021, then surged by 98.51% to -$6735.0 in 2022, then slumped by 3982.26% to -$274940.0 in 2023, then gained by 21.15% to -$216801.0 in 2024, then surged by 359.84% to $563340.0 in 2025.
- Business Quant data shows PPCB's Non Operating Income at $563340.0 in Q4 2025, -$164174.0 in Q3 2025, and -$426215.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | -51.63 Mn |
| 10 | Propanc Biopharma | 566,478.81 | 566,478.81 | - | 563,340.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 563,340.00 |
| Sep 30, 2025 | -164,174.00 |
| Jun 30, 2025 | -426,215.00 |
| Mar 31, 2025 | -938,633.00 |
| Dec 31, 2024 | -216,801.00 |
| Sep 30, 2024 | -63,520.00 |
| Jun 30, 2024 | -98,916.00 |
| Mar 31, 2024 | -106,108.00 |
| Dec 31, 2023 | -274,940.00 |
| Sep 30, 2023 | 66,353.00 |
| Jun 30, 2023 | -537,246.00 |
| Mar 31, 2023 | -425,316.00 |
| Dec 31, 2022 | -6,735.00 |
| Sep 30, 2022 | -44,465.00 |
| Jun 30, 2022 | -305,300.00 |
| Mar 31, 2022 | 39,707.00 |
| Dec 31, 2021 | -451,973.00 |
| Sep 30, 2021 | -4,628.00 |
| Jun 30, 2021 | -53,223.00 |
| Mar 31, 2021 | -102,063.00 |